Comparison in anticoagulation efficacy between rivaroxaban and warfarin after radiofrequency catheter ablation of atrial fibrillation

WANG Rui; ZHANG Wen-yong; WANG Wei

doi:10.3969/j.issn.1674-4055.2016.04.33

Abstract：Objective To compare the anticoagulation efficacy between rivaroxaban and warfarin in patients with atrial fibrillation (AF) after radiofrequency catheter ablation (RFCA).Methods AF patients undergone RFCA (n=100, male 57, female 43 and aged from 36 to 78) were chosen from Mar. 2013 to Apr. 2015, and randomly divided into rivaroxaban group and warfarin group (each n=50). The warfarin group was given warfarin (2.5 mg) every day after RFCA and rivaroxaban group was given rivaroxaban (10 mg) every day after RFCA. The curative effect was observed after 3 m. The international normalized ratio (INR) was detected before and after treatment. The incidence of thrombembolia and bleeding events were observed in 2 groups during treatment.Results INR was higher in rivaroxaban group than that in warfarin group [(2.6±0.4)vs. (1.9±0.5),P<0.05]. There were 41 patients controlled and the control rate was 82.0% in rivaroxaban group, and 25 controlled and the control rate was 50.0% in warfarin group (P<0.05). There was 1 patient (2.0%) with peripheral blood thrombembolia and 1 (2.0%) with mild bleeding in rivaroxaban group. There were 2 patients (4.0%) with thrombembolia (peripheral thrombosis and cerebral thrombosis), 5 with mild bleeding, 4 with less bleeding and 1 with severe bleeding in warfarin group. The bleeding rate was significantly lower in rivaroxaban group than that in warfarin group (2%vs. 20.0%,P<0.05). Conclusion Compared with warfarin, rivaroxaban can significantly improve anticoagulation efficacy and reduce bleeding rate with safe and reliable curative effect in AF patients undergone RFCA.